When was Novadip founded?

Novadip was founded in 2013 and raised its 1st funding round 2 years after it was founded.

Where is Novadip located?

Novadip is headquartered in Mont Saint Guibert, Belgium. It is registered at Rue Granbonpré 11 1435 Mont-Saint-Guibert.

How many employees does Novadip have?

As of Aug 31, 2026, the latest employee count at Novadip is 58.

Is Novadip a funded company?

Novadip is a funded company, having raised a total of $99M across 7 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 10, 2015.

When was the latest funding round of Novadip?

Novadip's latest funding was a $***** Series B round on Sep 21, 2026, with participation from 6 investors.

What is the annual revenue of Novadip?

Annual revenue of Novadip is less than €1M as on Dec 31, 2021

Where does Novadip rank among its competitors?

Novadip ranks 32nd amongst 2018 active competitors, of which 467 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Novadip?

Novadip's top competitors include Synthego, Antheia and Transcenta. Among them, Novadip secured the most recent funding round in September, 2026.

Novadip - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of stem cell-based therapies for bone healing disorders and bone defects. The company has developed regenerative therapeutics which include NVD-X3 for hard tissue reconstruction and NVD-X2 for soft tissue reconstruction. The m3 platform technology creost is a 3D osteogenic structure from autologous adipose-derived stem cells which reconstruct critical size bone defects without the use of any scaffold.

Website: novadip.com
Registered Address: Rue Granbonpré 11 1435 Mont-Saint-Guibert

Key Metrics

Founded Year

2013

Location

Mont Saint Guibert, Belgium

Stage

Series B

Total Funding

$99M in 7 rounds

Latest Funding Round

Series B, Sep 21, 2026, $*****

Investors

New Science Ventures & 15 more

Ranked

32^nd among 2018 active competitors

Annual Revenue

€0 - €1M as on Dec 31, 2021

Employee Count

58 as on Aug 31, 2026

Similar Companies

Synthego & 2743 more

View Novadip's full profile

Novadip is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Novadip Biosciences CIN: 0535.575.602 , Belgium, Active	May 30, 2013	€0 - €1M (As on Dec 31, 2021)	39 (As on Dec 31, 2021)	-

Novadip has raised a total funding of $99M over 7 rounds. Its first funding round was on Sep 10, 2015. Its latest funding round was a Series B round on Sep 21, 2026 for $*****. 6 investors participated in its latest round. Novadip has 14 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Novadip:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 21, 2026	4297028	Series B	7660152	7143577	2862222	4236484
2025	1926	Series B	8335	8430	1616	1308
Dec 15, 2023	6442258	Venture Debt	1007732	7743337	6040175	European Investment Bank

Access funding benchmarks and valuations. Sign up today!

View details of Novadip's funding rounds and investors

Novadip's employee count trend

Novadip has 58 employees as of Aug 26. Here is Novadip's employee count trend over the years:

Uncover Novadip's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Novadip include Synthego, Antheia and Transcenta. Here is the list of Top 10 competitors of Novadip, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, Perceptive Advisors & 30 others	71/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
3rd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
4th	Lineage Cell Therapeutics 1990, Carlsbad (United States), Public	Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders	$45.8M	State of California, Juvenescence & 4 others	66/100
5th	Judges Scientific 2002, London (United Kingdom), Public	Acquisition and development of scientific instrument businesses	-	Origin Capital, Lloyds Banking Group	65/100
6th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
7th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Fidelity Investments ... & 14 others	64/100
8th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Bpifrance & 14 others	63/100
9th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	UBS, Brown Brothers Harriman & 1 others	63/100
10th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$346M	Maverick Ventures, Polaris Partners & 16 others	62/100
32nd	Novadip 2013, Mont Saint Guibert (Belgium), Series B	Developer of stem cell-based therapies for bone healing disorders and bone defects	$99M	New Science Ventures, SFPI & 14 others	43/100